US Edition
Standard BioTools Inc. (LAB) Stock Analysis: Unpacking A Potential 75% Upside
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Standard BioTools Inc. (LAB) Stock Analysis: Unpacking A Potential 75% Upside
Standard BioTools Inc. (NASDAQ: LAB), headquartered in South San Francisco, California, is a prominent player in the healthcare sector, specifically within the medical devices industry. This company, which was formerly known as Fluidigm Corporation, has been on the radar of investors due to its innovative contributions in the fields of proteomics and genomics. With a market capitalization of approximately $487.68 million, Standard BioTools offer…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
